Home
Welcome Note
Congress Chairpersons
Faculty
Scientific Program
Satellite Symposia
Timetable
Abstract submission
Poster List
Poster Preparation Guidelines
Registration
Invitation Letter
Accommodation
Princesa Sofia Hotel
Sponsorship & Exhibition
Sponsors
CME Accreditation
EACCME
EHA - CME
General Information
Before you travel...
Transportation
Tips and Hints
About Barcelona
Italian Agent
Endorsements
Partners
COHEM 2010
Past Sponsors
Contact Us
Gallery
 
  Poster List Print
MONOSOMAL KARYOTYPE IN ACUTE MYELOID LEUKEMIA (AML)
E. Aguiar1, F. Trigo1, 2, P. Gomes1, J.E. Guimaraes1, 2
1 Centro Hospitalar Sao Joao, Porto, Portugal
2 Faculdade de Medicina da Universidade do Porto, Porto, Portugal

ELEVATED PREVALENCE OF AND IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH THROMBOEMBOLIC EVENTS OCCURING IN SICKLE CELL DISEASE
H. Algahtani
King Saud University Hospital, Saudi Arabia

DETERMINATING FREQUENCY OF MORTALITY AND THE CAUSES OF DEATH IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA REFERRED TO ALI ASGHAR HOSPITAL DURING 20 MARCH 2004–19 MARCH 2012
K.H. Arjmandi1, G. R. Bahoush2, L. Hashami2
1Department of Pediatric Hemato and Oncology, Aliasghar Children Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
2Pediatric Hematology and Oncology, AliAsghar Children Hospital, Tehran University of Medical Sciences

PONATINIB IN PATIENTS WITH CML AND PH+ ALL RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB OR WITH THE T315I MUTATION
M. Baccarani1, J. E. Cortes2, D. W. Kim3, J. Pinilla-Ibarz4, R. Paquette5, P. D. le Coutre6, C. Chuah7, F. E. Nicolini8, J. F. Apperley9, H. J. Khoury10, M. Talpaz11, J.F. DiPersio12, D. J. DeAngelo13, D. Rea14, E. Abruzzese15, M.C Mueller16, C. Gambacorti-Passerini17, C. D.Turner18, F. Haluska18, H.M. Kantarjian19
1Department of Hematology-Oncology 'L. and A. Seragnoli,' S Orsola-Malpighi University Hospital, Bologna, Italy
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
4H. Lee Moffitt Cancer Center, Tampa, FL, USA
5Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA, USA
6Charité – University of Medicine Berlin, Berlin, Germany
7Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore
8Centre Hospitalier Lyon Sud, Pierre Bénite, France
9Department of Haematology, Hammersmith Hospital, Imperial College London, London, UK
1
0Emory Winship Cancer Institute, Atlanta, GA, USA
11Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
12Washington University School of Medicine, St Louis, MO, USA
13Dana-Farber Cancer Institute, Boston, MA, USA
14Service des Maladies du Sang, Hopital Saint-Louis, Paris, France
16III. Med. Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
17Unità di Ricerca Clinica - Ematologia, Azienda Ospedaliera San Gerardo/University of Milano Bicocca, Monza, Italy
18ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA
1
9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

IMPACT OF POSACONAZOLE PROPHYLAXIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES
R. F. Bergantim1, 2, E. Aguiar1, T. Garrido1, F. Trigo1, 2, J.E. Guimarães1, 2
1Department of Clinical Hematology, Hospital São João, Porto – Portugal
2Faculty of Medicine, University of Porto, Porto – Portugal

LYMPHOCYTOSIS AFTER GLIVEC (IMATINIB MESYLATE)
E. Bratu
Clinical Institute fundeni Bucharest, Romania

THE WHO 2008 CLASSIFICATION OF MASTOCYTIC DISEASES DOES NOT ACCOMMODATE ETV6-ABL1 DISEASES. REPORT OF SUCH A CASE
M.C. Brito-Babapulle1, C.P. Cross 2, B. Czepulowski 3, S. Sadullah1, C. Gomez1
1James Paget University Hospital
2Wessex Regional Genetic Laboratory, Salisbury UK
3Dept of Cytogenetics, Kings college UK

90Y-IBRITUMOMAB TREATMENT FOR RELAPSED AND/OR REFRACTORY B CELL TYPE NON-HODGKIN'S LYMPHOMA. MULTIINSTITUTIONAL ARGENTINIAN STUDY. UP DATE
R.E. Cacchione1, R. Bezares2, G. Garay1, J. Bordone3, J. Milone4, G. Milone5 , L. Cerebrin6, J. Fedeles7, M. Furke8, J. Dupont1, M. Castro Rios9 C. Chiattone10
1 Cemic ba Argentina
2 Hospital Alvarez ba Argentina
3 Consultorios Oncologicos la Plata Argentina
4 Hospital Italiano la Plata Argentina
5 Fundaleu ba Argentina
6 Hospital Tornu ba Argentina
7 Consultorios Privados Santa Fe Argentina
8 Clinica San Carlos Rio Negro Argentina
9 Santorio San Lucas ba Argentina
10Santa casa medical school, San Paolo, Brasil

FUNCTIONAL PATHWAY ANALYSIS USING SINGLE CELL NETWORK PROFILING (SCNP) SHOWS PROGNOSTIC VALUE IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL): RESULTS OF TRAINING & TEST STUDIES
A. Cesano1, O. Perbellini2, E. Evensen1, F. Chioffi2, J. Ptacek1, R. Cignola3, J. Cordeiro1, R. E. Hawtin1, J. Ware1, C. Cavallini2,4, G. Pizzolo2, M. T. Scupoli2,4
1Nodality Inc., South San Francisco, CA USA
2Department of Medicine, Section of Hematology,
3Department of Biotechnology, University of Verona,
4Interdepartmental Laboratory for Medical Research (LURM), University of Verona

WASABI COMPOUND DERIVATIVES INDUCE CELL DEATH WITH CO-EXISTING MITOTIC ARREST AND AUTOPHAGY IN HUMAN CHRONIC MYELOGENOUS LEUKEMIA K562 CELLS INDEPENDENT TO IMATINIB RESISTANCE
Y. Chen1, H. F. Liao2, Z. H. Chen2
1Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan
2Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan

CTLA-4 IS AN ANTIPROLIFERATIVE FACTOR IN PERIPHERAL BLOOD MALIGNANT LYMPHOCYTES OF B-CLL PATIENTS
L. M. Ciszak1, A. I. Kosmaczewska1, A. Szteblich1, D. Wolowiec2, S. Potoczek2, K. Kuliczkowski2, I. Frydecka1, 2
1Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
2Medical University of Wroclaw, Wroclaw, Poland

ERYTHROBLASTIC SARCOMA, AN EXTREMELY RARE VARIANT OF MYELOID SARCOMA
B. Cornfield
Health Network Labs/Lehigh Valley Health Network, Allentown, PA USA

THE IMPACT OF HLA MISMATCHES ON UNRELATED HSCT OUTCOME – A SINGLE CENTRE RETROSPECTIVE STUDY
M. Dobrovolna, V. Valkova, M. Vrana, M. Markova, B. Prochazka, P. Cetkovsky
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
 
EFECTIVENESS OF AZACITIDINE TREATMENT IN MDS PATIENTS – A REPORT BY POLISH ADULT LEUKEMIA GROUP
J. Dwilewicz-Trojaczek1, J. E. Drozd-Sokolowska1, A. Waszczuk-Gajda1, K. Madry1, B. Stella-Holowiecka2, A. Kolkowska-Lesniak3, W. Knopinska-Posluszny4, A. Mital4, A. Szmigielska-Kaplon5, M. Wojciechowska6, A. Kopacz7, M. Zalewska8
1Department of Hematology, Oncology and Internal Medicine, The Medical University of Warsaw, Poland
2Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Poland
3Department of Hematology, Institute of Hematology and Transfusiology, Poland
4Department of Hematology and Transplantology, Medical University of Gdansk, Poland
5Department of Hematology, Medical University of Lodz, Poland
6Department of Hematology, Voivodal Specialistic Hospital in Olsztyn, Poland
7Department of Hematology, Voivodal Specialistic Hospital of Rzeszow, Poland
8Department of Hematology, Specialistic Hospital of Torun, Poland

NPM1 MUTATION IN ACUTE MYELOID LEUKEMIA: A STUDY OF 1068 CASES
H.L. Drum, P. Reddy, P. Petersen, K. Lin, E. Wei, R. Mohrmann, B. Dabbas
Genoptix Medical Laboratory, a Novartis Company, Carlsbad, USA

ANTI DS DNA TEST AS PREDICTOR OF CHRONIC ANEMIA DISEASES
I. Guanchez1, M. Jimenez1, D. Lopez1, D. Martinez2, E. Parada1
1Universidad de Oriente, Cuba
2Hospital Universitario Dr. Luis Razetti, Barcelona, Spain

LENALIDOMIDE FOR TREATMENT OF LOW RISK MYELODYSPLASTIC SYNDROMES AND HIGHT TRANSFUSIONAL REQUIREMENTS
I. Guanchez 1 , S. A. Gomez 1, A. Kovacic1 , E. Malave 1, M. Ovalles 1, D. Martinez 2
1Universidad de Oriente, Cuba
2Hospital Universitario Dr. Luis Razetti, Barcelona, Spain


CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF PEDIATRIC THERAPY-RELATED ACUTE MYELOID LEUKEMIA
K. T. Hong, N. H. Kim, J. W. Lee, M. S. Kim, H. Kim, H. J. Kang, K. D. Park, H. Y. Shin, H. S. Ahn
Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

SPLENECTOMY- THERAPEUTIC OPTION IN PATIENTS WITH IMMUNE THROMBOCITOPENIC PURPURA
I. I. Ionita, I. C. Ionita, C. M. Cheveresan, C. I. Cheveresan, I. M. Ionita, C. D. Calamar, O. D. Oros, I. H. Ionita
University of Medicine and Pharmacy "Victor Babes", Timisoara, Romani

THE EVALUATION OF CLINICO-BIOLOGICAL AND IMMUNOLOGICAL PARAMETERS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
I. I. Ionita, C. L. Cheveresan, C. D. Calamar, C. I. Ionita, O. D. Oros, I. M. Ionita, I. H. Ionita
University of Medicine and Pharmacy "Victor Babes", Timisoara, Romania

THE RETROSPECTIVE STUDY OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA - SINGLE INSTITUTION EXPERIENCE
I. I. Ionita, I. C. Ionita, C. L. Cheveresan, I. M. Ionita, C. D. Calamar, I. H. Ionita
University of Medicine and Pharmacy "Victor Babes", Timisoara, Romania

LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
I. H. Ionita, I. I. Ionita, C. M. Cheveresan, I. C. Ionita, O. D. Oros, I. M. Ionita
University of Medicine and Pharmacy "Victor Babes", Timisoara, Romania

PRESENTING FEATURES AND EVOLUTION OF ACUTE MYELOID LEUKEMIA PATIENTS AT A UNIVERSITY HOSPITAL IN NORTHEAST MEXICO
C. Jaime-Pérez, S. Brito-Ramírez, A. Pinzón-Uresti, Gutiérrez-Aguirre, G. Cantú-Rodríguez, L. Herrera-Garza, Gómez-Almaguer
Hematology Department, University Hospital of the Autonomous University of Nuevo León

THE ROLE OF CLONAL CYTOTOXIC T CELLS IN MULTIPLE MYELOMA
D. E. Joshua1,2, R. Brown1,2, J. Gibson1,2, P. Joy Ho1,2, H. Suen1,2, S. Yang1,2, J. Favaloro1,2
1Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
2Bosch Institute, University of Sydney, Australia

PEDIATRIC ACUTE MEGAKARYOCYTIC LEUKEMIA: A CASE REPORT
A. Kanungo, K. Janatpour, B. Dabbas
Genoptix Medical Laboratory, Carlsbad, California, USA

ANTITHROMBIN-III BASED TREATMENT FOR VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
J. W. Lee, H. J. Kang, N. H. Kim, K. T. Hong, M. S. Kim, H. Kim, K. D. Park, H. Y. Shin, H. S. Ahn
Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

SPHINGOSIN-1-PHOSPHATE INDUCES MEGAKARYOCYTIC DIFFERENTIATION THROUGH THE UPREGULATION OF JAK/STAT3 SIGNALING PATHWAY
H. F. Liao 1, 2, Y. J. Chen 2, 3, H. Y. Peng 1
1Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan
2Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan
3Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan

NEXT/VENICE: TWO PHASE IV, LONGITUDINAL STUDIES EVALUATING THE SAFETY PROFILE OF NIVESTIM IN CHEMOTHERAPY PATIENTS
F. Maloisel 1, D. Kamonier 2, S. Fruehauf 3, S. Lepretre 4, C. Berthou 5, L. Cals 6
1Clinique Saint Anne, Department of Hematology and Oncology, Strasbourg, France
2Hôpital Privé de l'Ouest Parisien, Trappes, France
3Paracelsus-Klinik, Center for Tumor Diagnostics and Therapy, Osnabrück, Germany
4Centre Henri Becquerel, Département d'Hématologie, Rouen, France
5Hôpital Morvan, Département d'Clinique Hématologie, Brest, France
6CHRU de Besançon, Besançon, France

STUDYING THE ROLE OF BAFF AND BAFF-R-FC FUSION PROTEIN ON LYMPHOCYTES AND PLATELETS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
N. N. Momen, S. K. Hussein, R. M. Fawzy, N.I. Sewelam, D. A. Mokhtar
Faculty of medicine Al kasr al ainy, Cairo, Egypt

LYMPHOMA VERSUS INFECTIOUS MONONUCLEOSIS: STILL A CHALLENGING DIAGNOSIS
C. Montoya, C. Gentile, E. Coyle, E. Hutchison
SUNY Upstate Medical University, Syracuse, USA

THE HIGH EXPRESSION OF BCRP MRNA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ADULT ACUTE MYELOID LEUKEMIA ASSOCIATED WITH MLL-PTD
B. Nasilowska-Adamska 1, I. Solarska 1, M. Paluszewska 2, W.W. Jedrzejczak 2, B. Marianska 3, K. Warzocha 3
1Institute of Hematology and Transfusion Medicine, Warsaw, Poland
2Medical University, Warsaw, Poland
3Institute of Hematology and Transfusion Medicine, Warsaw, Poland

UKRAINIAN EXPERIENCE IN THE USE OF THALIDOMIDE IN THE TREATMENT OF MULTIPLE MYELOMA
O. I. Novosad 1, Y. A. Stepanishina 1, I. A. Kryachok 1, T. V. Kadnikova 1, E. M. Aleksik 1, I. B. Titorenko 1, E. V. Kuschevoy 1, Y. V. Pastushenko 1, K. S. Filonenko 1, A. V. Martynchik 1, E. O. Ulyanchenko 1, N. I. Kostyukova 2, I. A. Filonenko 3, U. A. Gusachenko 3, P. E. Kaplan 4, A. V. Usenko 4, V. V. Stratienko 5, Z. V. Martina 6, S. N. Kravchenko 6, T. V. Malinkina 6, V. V. Sholoyko 6, A. A. Tovstogan 6
1 National Cancer Institute, Kiev, Ukraine
2 CBTM, Kiev, Ukraine
3 RH, Poltava, Ukraine
4 RH № 4, Dnepropetrovsk, Ukraine
5 RH, Kherson, Ukraine
6 Scientific Center of Radiation Medicine, Kiev, Ukraine
 
PLATELET'S ALTERATIONS AFTER SIMULATES DIVINS IN HYPERBARIC CAMERA
E. A. Paoletti 1, C. Espinosa 2, R. Laguens 3, G. Mauvecin 2, A. N. Garcia 1, M. E. Paoletti 1, C.W. Garcia 1
1Clinica 25 de Mayo-Universidad Fasta Mar Del Plata Argentina
2Centro de Medicina Hiperbarica de Mar Del Plata Argentina
3Fundacion Favaloro Buenos Aires Argentina

EUTOS CML PROGNOSTIC SCORING SYSTEM PREDICTS ELN-BASED 'EVENT-FREE SURVIVAL' BETTER THAN EURO/HASFORD AND SOKAL SYSTEMS IN CML PATIENTS RECEIVING FRONT-LINE IMATINIB MESYLATE
B. U. Uz 1, Y.B. Buyukasik 1, H. A. Atay 2, E. K. Kelkitli 2, M. T. Turgut 2, O. B. Bektas 1, E. A. Eliacik 1, A. L. Isik 1, S. A. Aksu 1, H. G. Goker 1 N. S. Sayinalp 1, I. C. H. Haznedaroglu 1
1Hacettepe University, Division of Hematology, Ankara, Turkey
2Ondokuz Mayıs University, Department of Hematology, Samsun, Turkey

LONG-TERM FOLLOW-UP OF FOLLICULAR LYMPHOMA TREATED WITH IBRITUMOMAB TIUXETAN-ITRIUM (ZEVALIN®) IN CONSOLIDATION
P. Viveiros, M. L. Neves, C. Lopes, G. Esteves, S. Valle, J. Fajardo, B. Gomez, C. Martins, E. Luís, J. C. Raposo, J. A. Carmo
Serviço de Hematologia e Transplantação de Medula – Hospital de Dia de Hematologia Centro Hospitalar Lisboa Norte, EPE – Hospital de Santa Maria, Lisboa, Portugal

INFECTIONS ASSOCIATED WITH CHRONIC GRANULOMATOUS DISEASE. IS THERE GENETIC LINKAGE BETWEEN THE GENOTYPE TO THE PHENOTYPIC EXPRESSION OF THE DISEASE? NEW INSIGHTS ON DIAGNOSIS, MANAGEMENT AND PREVENTION OF INFECTIONS
B. J. Wolach 1, 2, Gavrieli 2
1Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
2The Laboratory for Leukocyte Functions & The Pediatric Immuno-Hematology Clinic, Meir Medical Center, Kfar Saba and The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

AUTOLOGOUS STEM CELL TRANSPLANTATION IN T-CELL NON-HODGKIN'S LYMPHOMAS – LONG-TERM FOLLOW-UP
W. Zinke-Cerwenka 1, A. Valentin 1, C. Beham-Schmid 2, M. Eibl 1, W. Linkesch 1, P. Neumeister 1
1Division of Hematology, Austria
2Institute of Pathology, Medical University of Graz, Austria

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 12/04/2013 Created by     WebStudio.co.il